CDMO & Manufacturing

Tozaro develops Smart Polymers, a novel class of synthetic affinity ligands designed to improve viral vector purification and analytics for cell and gene therapies. Their computational chemistry and machine learning platform enables cost-effective manufacturing of lentiviral vectors for CAR-T treatments and AAV vectors, with applications in downstream processing and quality control. The company's technology uses over 600 chemical monomers to create custom affinity solutions that outperform traditional biological reagents, helping pharmaceutical manufacturers reduce per-dose costs while improving yield and recovery rates.

TQ Therapeutics develops innovative technologies for cell and gene therapy manufacturing, including the EXiVO extracorporeal approach for ultra-fast, automated processing of autologous T cells using mRNA-LNP. Their platform enables bedside delivery of personalized therapies in under five hours by integrating blood collection, cell isolation, genetic modification, and reinfusion. They license proprietary affinity-based cell selection technology to partners like Fresenius Kabi for scalable T-cell isolation from whole blood.

Trenchant Biosystems develops the AutoCell platform for automating patient-specific cell and gene therapy (CGT) manufacturing, enabling scalable production in ISO class 7 environments at the place of care. The technology uses microbubble separation to achieve 7-fold higher gene-modified cell yields, reduce costs by up to 80%, and shorten vein-to-vein timelines from six weeks to 2.5 days. Partnerships with Invetech, UMass Chan Medical School, and Caring Cross advance the platform toward fully automated commercial products for applications like sickle cell disease therapies.

eXmoor Pharma is a full-service CDMO specializing in cell and gene therapy manufacturing, offering end-to-end solutions from CMC strategy and process development to GMP production and facility design. Founded in 2004 and headquartered in Bristol, UK, the company supports innovators with over 20 years of consultancy experience, having completed 500+ projects for 150+ organizations. Their flexible GMP facility includes Grade C cleanrooms for viral vectors, autologous, and allogeneic therapies, with plans to expand to 200 employees by 2027.

Nanoworx is a Contract Research Organization (CRO) based in Eindhoven, Netherlands, specializing in nanomedicine development and optimization. The company offers nanoparticle design, high-throughput library construction and screening, production at scale, and in vitro assay testing to support clients from early-stage concepts through clinically-ready nanomedicines. Nanoworx leverages automated production platforms and deep expertise to bridge the manufacturability gap in nanomedicine translation.

Quanta Therapeutics develops oral, allosteric small molecule inhibitors targeting undruggable RAS mutations like KRAS G12D and G12V for RAS-driven cancers, including pancreatic, colorectal, lung, and endometrial types. Their Phase 1 pipeline includes QTX3034 (G12D-preferring multi-KRAS), QTX3046 (G12D-selective), and QTX3544 (G12V-preferring multi-KRAS), with CNS-penetrant properties and preclinical proof-of-concept. The company leverages Second Harmonic Generation (SHG) technology for protein conformation detection and has sites in South San Francisco, CA, and Radnor, PA.